According to this, in a series of 150 CRC cases, the combination of CD68 as a macrophage lineage marker, CD80 as a marker of anti-tumor (M1) macrophages, and CD163 as a marker of pro-tumor (M2) macrophages has corroborated that distinct macrophage subtypes are differentially distributed throughout the tumor and are associated with different outcomes [158]. The gene discussed is CD163; the disease is neoplasm.